Strategy Asset Managers’s Vertex Pharmaceuticals VRTX Stock Holding History

Strategy Asset Managers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.41M	Sell	3,164 -27	-0.8%	-$12.6K	0.23%	76
2025 Q4	$1.45M	Buy	3,191 +198	+7%	+$85.3K	0.24%	71
2025 Q3	$1.17M	Buy	2,993 +51	+2%	+$21.3K	0.21%	79
2025 Q2	$1.31M	Buy	2,942 +99	+3%	+$45.6K	0.24%	73
2025 Q1	$1.38M	Buy	2,843 +229	+9%	+$107K	0.28%	69
2024 Q4	$1.05M	Sell	2,614 -95	-4%	-$44K	0.2%	86
2024 Q3	$1.26M	Sell	2,709 -1,805	-40%	-$867K	0.24%	74
2024 Q2	$1.59M	Buy	4,514 +2,116	+88%	+$918K	0.35%	58
2024 Q1	$1M	Sell	2,398 -1,490	-38%	-$630K	0.21%	77
2023 Q4	$1.58M	Sell	3,888 -188	-5%	-$69.5K	0.38%	54
2023 Q3	$1.42M	Sell	4,076 -438	-10%	-$153K	0.37%	55
2023 Q2	$1.59M	Buy	4,514 +264	+6%	+$89K	0.35%	58
2023 Q1	$1.34M	Buy	4,250 +2,488	+141%	+$746K	0.33%	62
2022 Q4	$509K	Hold	1,762	–	–	0.13%	131
2022 Q3	$510K	Buy	1,762 +435	+33%	+$125K	0.14%	135
2022 Q2	$374K	Buy	1,327 +139	+12%	+$37.2K	0.12%	124
2022 Q1	$310K	Buy	+1,188	New	+$282K	0.07%	198

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Strategy Asset Managers's VRTX Position: Q1 2026 in Review

Strategy Asset Managers reduced its Vertex Pharmaceuticals (VRTX) stake by 0.85% in Q1 2026, selling an estimated $12.6K and leaving 3,164 shares worth $1.41M. The position accounts for 0.23% of the portfolio, ranked #76.

Strategy Asset Managers first reported a position in VRTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.59M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Strategy Asset Managers held 3,164 shares of Vertex Pharmaceuticals worth $1.41M as of Q1 2026.
Strategy Asset Managers sold 27 Vertex Pharmaceuticals shares in Q1 2026, an estimated $12.6K.
Vertex Pharmaceuticals made up 0.23% of Strategy Asset Managers's portfolio in Q1 2026, its #76 holding.
Strategy Asset Managers first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
Strategy Asset Managers's Vertex Pharmaceuticals position peaked at $1.59M in Q2 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Strategy Asset Managers's 13F filing for Q1 2026, filed 12 May 2026.